The Series A round was led by BOLD Capital Partners, Supernova Invest and Sanara Capital, with participation from multiple U.S. hospital networks, orthopedic surgeons, veteran medtech industry investors and existing investors, according to a Sept. 10 press release.
Discure’s device earned the FDA’s breakthrough device designation in 2021, conducting its first in-human trials in Canada and Italy.
Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat and reverse degenerative disc disease by controlling the reintroduction of fluid, oxygen and nutrients into the affected disc.
Unlike existing treatments, the Discure system has the potential to be the first disease-modifying solution for DDD, designed to reduce the use of opioids and the need for invasive back surgery.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
